Table 1. Demographic and clinical characteristics of patients with LS-SCLC.

Variables	All patients (N=226) N% or median value [range]	Pre-treatment absolute lymphocyte count				Absolute lymphocyte count after chemoradiation
		ALC <1,780 cells/mm3 (N=108)	ALC ≥1,780 cells/mm3 (N=118)	P		ALC <655 cells/mm3 (N=138)	ALC ≥655 cells/mm3 (N=88)	P
Age, years	63 [28–82]	63 [38–82]	62 [28–79]	0.361		63 [28–82]	60.5 [35–75]	0.011
Sex				0.184				0.411
Male	171 (75.7)	86 [80]	85 [72]			107 [78]	64 [73]
Female	55 (24.3)	22 [20]	33 [28]			31 [22]	24 [27]
Smoking status				0.387				0.888
Never smoker	84 (37.2)	37 [34]	47 [40]			52 [38]	32 [36]
Current or ex-smoker	142 (62.8)	71 [66]	71 [60]			86 [62]	56 [64]
KPS at diagnosis				0.264				0.114
≥80	204 (90.3)	95 [88]	109 [92]			128 [93]	76 [86]
<80	22 (9.7)	13 [12]	9 [8]			10 [7]	12 [14]
Prophylactic cranial irradiation				0.775				0.039
Yes	67 (29.6)	33 [31]	34 [29]			34 [25]	33 [38]
No	159 (70.4)	75 [69]	84 [71]			104 [75]	55 [62]
Radiotherapy fractionation				0.452				0.007
Conventional fractionated RT	145 (64.2)	72 [67]	73 [62]			79 [57]	66 [75]
Hyperfractionated RT	81 (35.8)	36 [33]	45 [38]			59 [43]	22 [25]
Response for CRT				0.392				0.441
CR	16 (7.1)	8 [7]	8 [7]			10 [7]	6 [7]
PR	182 (80.5)	89 [83]	93 [79]			111 [81]	71 [81]
SD	13 (5.8)	7 [6]	6 [5]			10 [7]	3 [3]
PD	15 (6.6)	4 [4]	11 [9]			7 [5]	8 [9]
Hemoglobin (Hb)	142 [92–179]	142 [92–172]	144 [106–179]	0.021		142 [92–179]	143 [98–170]	0.259
Alkaline phosphatase (Alp)	86 [47–239]	86 [49–239]	84 [47–234]	0.201		87 [47–234]	88 [49–239]	0.125
Albumin (Alb)	42 [20–79]	42 [20–49]	42 [25–79]	0.622		42 [20–51]	42 [25–79]	0.383
Lactic dehydrogenase (LDH)	192 [121–1,085]	188 [133–710]	189 [121–1,085]	0.618		198 [121–710]	188.5 [135–1,085]	0.778
Pre-ALC	1,890 [703–3,018]
After-ALC	540 [10–1,600]
Post-ALC	1,300 [630–2,140]

LS-SCLS, limited-stage small cell lung cancer; ALC, absolute lymphocyte count; CR, complete response; PR, partial response; PD, progressive disease; SD, stable disease.